Adam Wierzbowski has represented investors and other plaintiffs in numerous complex litigations that include securities class actions and derivative suits.
Adam was a senior member of the team that recovered over $1.06 billion on behalf of investors in In re Merck Vioxx Securities Litigation, which arose out of the Defendants’ alleged misrepresentations about the cardiovascular safety of Merck’s painkiller Vioxx. The case was settled just months before trial and after more than 10 years of litigation. During that time, Plaintiffs achieved a unanimous and groundbreaking victory for investors at the U.S. Supreme Court. The settlement is the second largest recovery ever obtained in the Third Circuit, among the 15 largest recoveries of all time, and the largest securities recovery ever achieved against a pharmaceutical company.
Adam was also a senior member of the team that achieved a total settlement of $688 million on behalf of investors in In re Schering-Plough Corp./ENHANCE Securities Litigation and In re Merck & Co., Inc. Vytorin/Zetia Securities Litigation, which related to Schering and Merck’s alleged misrepresentations about the multi-billion dollar blockbuster drugs Vytorin and Zetia. The combined $688 million in settlements is the third largest securities class action settlement in the Third Circuit and among the top 25 securities class action settlements of all time. The cases settled after nearly five years of litigation and less than a month before trial.
More recently, Adam was a senior member of the team that obtained $480 million for investors in the securities class action against Wells Fargo & Co. related to its fake accounts scandal. The settlement is the fourth largest settlement in the Ninth Circuit.
In the UnitedHealth Derivative Litigation, which involved executives’ illegal backdating of UnitedHealth stock options, Adam also helped recover in excess of $920 million from the individual Defendants. He also represented investors in the securities litigation against General Motors and certain of its senior executives stemming from that company’s delayed recall of vehicles with defective ignition switches, where the parties recovered $300 million for investors, in the second largest securities class action recovery in the Sixth Circuit.
Adam also helped obtain significant recoveries on behalf of investors in Minneapolis Firefighters’ Relief Association v. Medtronic, Inc. et al. ($85 million recovery); Bach v. Amedisys, et al. ($43.75 million recovery); In re Facebook, Inc., IPO Securities and Derivative Litigation ($35 million recovery); In re Altisource Portfolio Solutions, S.A. Securities Litigation ($32 million recovery) and the Monster Worldwide Derivative Litigation (recovery valued at $32 million). He is currently a member of the teams prosecuting In re EQT Corporation Securities Litigation; Allegheny County Employees' Retirement System, et al. v. Energy Transfer LP, et al.; In re Myriad Genetics, Inc. Securities Litigation; Stichting Depositary APG, et al. v. Synchrony Financial, et al.; and In re Celgene Corporation Securities Litigation.
In 2016, Adam was named to Benchmark Litigation’s “Under 40 Hot List,” in recognition of his achievements as one of the nation’s most accomplished legal partners under the age of 40. He is also regularly named as one of Thomson Reuter’s Super Lawyers and a New York “Rising Star.” No more than 2.5% of the lawyers in New York are selected to receive this honor each year. The New York Law Journal also named him a 2019 “Rising Star.” Most recently, he was named a 2020 "500 Leading Plaintiff Financial Lawyer" by Lawdragon.